SecBot SecBot

JNJ drug pipeline

JOHNSON & JOHNSON · 17 rated drugs
$282.55
−1.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±0.7%
1-day, median of 40 events
IV rank
60
IV 25% · HV 30%
Rated drugs
17
3 bullish · 1 mixed · 13 neutral
Phase 3 trials
13
1 with results posted

Upcoming catalysts

9 dated
  1. Dec 1, 2026
    ERLEADA
    Phase 3 primary completion
  2. Dec 8, 2026
    Milvexian
    Phase 3 primary completion
  3. Dec 22, 2026
    JNJ-64042056
    Phase 2 primary completion
  4. Dec 30, 2026
    Cetrelimab
    Phase 3 primary completion
  5. Dec 31, 2026
    Ibrutinib
    Phase 3 primary completion
  6. Jan 31, 2027
    RYBREVANT FASPRO
    Phase 2 primary completion
  7. Feb 4, 2027
    IMAAVY
    Phase 3 primary completion
  8. Feb 10, 2027
    Icotrokinra
    Phase 3 primary completion
  9. Feb 10, 2027
    Guselkumab Subcutaneous
    Phase 3 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
Time to marketAlready approved and on the market — DARZALEX (IV) since Nov 2015 and DARZALEX FASPRO (subcutaneous) since May 2020; label expansion for newly diagnosed multiple myeloma added ~Jan 2026.

DARZALEX daratumumab Updated Aug 17

What to watch

For JNJ shareholders, DARZALEX is a cash-cow growth driver, not a binary, treat it as part of the Innovative Medicine growth story (with CARVYKTI, TREMFYA, SPRAVATO) that supported the FY2026 guidance raise, and watch each Genmab 6-K for quarterly DARZALEX net sales as the cleanest read on the franchise. The bigger near-term event to track is competitive: Bristol Myers' iberdomide + daratumumab + dexamethasone PDUFA landed Aug 17, 2026, and BMY's bb2121 CAR-T Phase 3 readout is pending.

Bull case
  • Record commercial scale: Q2 2026 worldwide net sales of DARZALEX were USD 4,207M (US $2,435M; rest of world $1,772M), disclosed in Genmab's 6-K filed 2026-07-15, up from $3.964B in Q1 2026.
  • J&J Q2 2026 earnings analysis (8-K filed 2026-07-15) credits DARZALEX, alongside CARVYKTI, TREMFYA and SPRAVATO, for driving the quarter and the raise of FY2026 adjusted EPS guidance to $11.68 at the midpoint.
  • Continuous label expansion: FDA supplemental approval for IV daratumumab on 2025-04-10 and a ~Jan 2026 sBLA approval of DARZALEX FASPRO + bortezomib/lenalidomide/dexamethasone for newly diagnosed multiple myeloma (per local FDA catalyst/action records).
Bear case
  • No hard, dated binary for the drug itself in the next ~12 months, no pending PDUFA or pivotal readout is logged locally, so DARZALEX cannot be a high-impact single-stock catalyst; for JNJ it is one growth driver among several (CARVYKTI, TREMFYA, SPRAVATO), and for Genmab it is royalty-dependent revenue.
  • Competitive pressure is mounting: BMS' iberdomide + daratumumab + dexamethasone had a PDUFA target date of 2026-08-17 (local event ledger), and BMS' bb2121 CAR-T Phase 3 (386 patients) completed 2026-04-13 with results not yet posted.
  • Intra-company cannibalization risk: J&J's own CAR-T (JNJ-68284528, Phase 2 NCT04133636, ~210 patients, primary completion est. 2026-08-04) and bispecifics can shift later-line patients away from DARZALEX combos.
◆ mixed
Impact
PhaseApproved (first indication); NDA under FDA review for wAIHA
Time to marketAlready approved and commercializing (FDA approval catalyst recorded 2025-04-29). The wAIHA label expansion decision is undated in available data; a standard NDA review would land roughly a year from the April 14, 2026 submission.

IMAAVY nipocalimab Updated Aug 18

What to watch

Watch for FDA acceptance of the wAIHA NDA and a PDUFA date (likely announced via a J&J press release/8-K; a standard ~10-month review from the April 2026 filing would point to early 2027). For JNJ holders this is a slow-burn label-expansion story, not a binary event, the approval day moved the stock only +0.62% and the NDA submission +0.3%, so size any position accordingly. Track the gMG/wAIHA competitive field (VYVGART, cemdisiran, sovleplenib, povetacicept) and quarterly IMAAVY sales disclosures.

Bull case
  • Already FDA-approved: local catalyst records show an FDA approval for IMAAVY at JNJ on 2025-04-29 (price +0.62% on the day), the first regulatory binary has passed and commercialization is underway.
  • Label expansion in flight: J&J submitted an NDA for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia on 2026-04-14, recorded with high confidence and tied to the 8-K filed that day.
  • More runway: nipocalimab received U.S. FDA Fast Track designation for systemic lupus erythematosus (SLE) on 2026-04-14.
Bear case
  • Tiny share-price impact: IMAAVY's approval day moved JNJ only +0.62% (1-day) and the 2026 NDA submission only +0.3%, the drug is a small fraction of a mega-cap's value, and JNJ FDA-approval catalysts averaged -0.21% 1-day across 11 approvals in the dataset.
  • No dated binary on record: the wAIHA NDA (filed 2026-04-14) has no recorded PDUFA date, so there is no hard, dated catalyst in the next ~12 months; NDA submissions are weak non-binary events.
  • Crowded gMG competition: VYVGART Hytrulo (HALO) approved for gMG 2026-05-01 and 2026-05-11, VYVGART seronegative-gMG PDUFA (ZLAB) 2026-05-10, cemdisiran NDA submissions (REGN/ALNY) in 2026, and UPLIZNA gMG PDUFA (AMGN) 2025-12-14 all target the same antibody-lowering space.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2019 (adjunctive TRD) and expanded to monotherapy in January 2025.

SPRAVATO esketamine Updated Nov 10

What to watch

Spravato is a steady growth contributor within JNJ's broader Innovative Medicine segment, not a binary catalyst for the stock. Watch for quarterly sales trends as a read on commercial adoption, and monitor the COMP360 psilocybin NDA (submitted November 2026) as potential future competition in the treatment-resistant depression space.

Bull case
  • Spravato has shown consistent quarter-over-quarter sales growth, with Jefferies analysts citing its momentum as supporting the commercial viability of psychedelic-based mental health treatments.
  • The January 2025 FDA approval as a monotherapy (the first and only for TRD) significantly expanded the addressable patient population beyond the original adjunctive-only label.
  • JNJ won a patent infringement case against Sandoz in September 2026, protecting Spravato from generic competition and extending its market exclusivity.
Bear case
  • Spravato requires administration in a certified healthcare setting under a REMS program, with monitoring for sedation and dissociation, which limits patient access and convenience (up to ~50 visits per year per the VA).
  • Compass Pathways submitted an NDA for COMP360 psilocybin for TRD in November 2026, which could become the first FDA-approved classic psychedelic and compete for the same patient population.
  • As a Schedule III controlled substance, Spravato faces regulatory and prescribing barriers that oral, non-controlled antidepressants do not.
▲ bullish
Impact
PhaseApproved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
Time to marketAlready approved and marketed — U.S. approval since July 13, 2017 (plaque psoriasis); newest indication (Crohn's disease) approved May 28, 2026.

TREMFYA guselkumab Updated Aug 17

What to watch

TREMFYA is J&J's key immunology growth engine (Q2 2026 sales +72.5% YoY per J&J's earnings analysis), but the bull/bear is now about commercial ramp and IBD share gains vs. AbbVie's Skyrizi, not a binary event. Watch the pending Phase 3 pediatric juvenile psoriatic arthritis readout (NCT05083182, trial completed June 2026, results not yet posted), quarterly TREMFYA sales, and any payer/formulary headlines in UC/Crohn's.

Bull case
  • Two major label expansions landed within ~8 months: FDA supplemental efficacy approvals for guselkumab (SC/IV) on 2025-09-26 and 2026-05-28, corresponding to the ulcerative colitis and Crohn's disease expansions (FDA BLA 761061 records).
  • Fast-growing franchise: J&J's Q2 2026 earnings analysis lists TREMFYA (+72.5% YoY) among the top growth drivers of Innovative Medicine, alongside DARZALEX, CARVYKTI and SPRAVATO (SEC 8-K analysis, filed 2026-07-15).
  • Royalty holder Royalty Pharma reported ~14% royalty-receipts growth in Q2 2026 driven partly by Tremfya and raised full-year guidance (RPRX Q2 2026 earnings analysis).
Bear case
  • Biosimilar risk demonstrated in-house: J&J's own STELARA, the same immunology class, same company, fell 55.2% YoY in Q2 2026 due to biosimilar competition, showing what eventually awaits TREMFYA's IL-23 franchise (J&J Q2 2026 earnings analysis).
  • Intense IBD competition: AbbVie's Skyrizi (also an IL-23 blocker) plus Rinvoq, Entyvio/Omvoh and emerging oral agents; local press records show Abivax's obefazimod on track for an NDA submission in Q4 2026 and Alvotech's Entyvio biosimilar BLA accepted, pressuring the IBD market TREMFYA just entered.
  • No upcoming binary catalyst: both new-indication approvals are behind it, so near-term upside depends on quarterly commercial execution and payer/formulary outcomes, which are not hard dated events.
▲ bullish
Impact
PhaseApproved (marketed); ongoing Phase 2/3 studies
Time to marketAlready approved and commercially marketed (US and other regions, approved since 2022; earlier-line use since 2024); ongoing trials support further expansion.

CARVYKTI ciltacabtagene autoleucel Updated Aug 17

What to watch

For JNJ holders, CARVYKTI is a slow-burn growth contributor, watch the quarterly net-trade-sales updates and any early-line label moves, but don't expect a stock-moving binary.

Bull case
  • Fast-growing franchise: CARVYKTI net trade sales ~$657M in Q2 2026 (+50% YoY), ~$597M in Q1 2026 (+62% YoY), and $1.9B for full-year 2025, per Legend's earnings filings, which drove Legend's first-ever quarterly net income ($33.2M) and franchise profitability.
  • Durable efficacy: ASCO 2026 data showed 30-month overall survival >85% among CARTITUDE-4 responders, reinforcing the drug's position in earlier-line multiple myeloma; commercial footprint now spans 18 countries with 10,000+ patients treated.
  • JNJ's Q2 2026 beat (adjusted EPS $2.90 vs $2.85 consensus) and full-year guidance raise explicitly cited CARVYKTI among Innovative Medicine drivers (with DARZALEX, TREMFYA, SPRAVATO).
Bear case
  • Immaterial to JNJ's stock: CARVYKTI's ~$657M quarterly net trade sales are a low-single-digit slice of JNJ's $25.31B quarterly revenue; analysts see only ~6.7% implied upside at JNJ, so the drug cannot move the mega-cap much either way.
  • Dilution at the co-developer: Legend sold ~7.7M ADSs at $29.35 in June 2026 (~$226M offering, 424B5), and LEGN short interest rose to 18.1M shares (9.75% of ESTIMATED shares outstanding, +28.7% in the 7/31/2026 settlement) with a FINRA daily short-volume flow ratio ~0.51, above the 0.30 bearish threshold (this is short-sale flow, not outstanding short interest).
  • Leadership/execution risk at the co-developer: Legend CEO Ying Huang resigned effective July 24, 2026 (interim CEO Alan Bash appointed), and UBS downgraded LEGN Buy-to-Neutral (7/24) and Oppenheimer Outperform-to-Perform (8/12/2026); Legend's Q2 6-K also flags PRC transfer-pricing negotiations as a tax overhang.
● neutral
Impact
PhaseApproved / marketed
Time to marketAlready on the market — FDA approved May 20, 2011 (adults); pediatric formulation (EDURANT PED) approved March 15, 2024.

EDURANT rilpivirine Updated Aug 18

What to watch

For a JNJ investor, EDURANT is immaterial to the thesis: it is a mature, already-approved HIV pill inside a mega-cap whose value is set by far larger franchises (per JNJ's 10-Q/earnings filings), and no pivotal or regulatory binary is scheduled for this molecule. The only scheduled item to watch is primary completion of the pediatric roll-over study (NCT02494986, est. 2026-08-18); treat any news around it as routine label-support data, not a re-rating event. The more interesting rilpivirine exposure is the long-acting injectable space (cabotegravir + rilpivirine) being developed with ViiV/GSK, but that is a GSK-led program (NCT05917509, Phase 3, completed 2026-04-20), not a JNJ-only catalyst.

Bull case
  • Long-established approved product: FDA approval catalyst recorded 2011-05-20 (adult) and 2024-03-15 (EDURANT PED pediatric), an approved, marketed drug with a 15-year safety/commercial track record.
  • Rilpivirine remains strategically relevant in the growing long-acting injectable HIV space: a ViiV/GSK Phase 3 trial of cabotegravir + rilpivirine LA (NCT05917509) completed in 2026, extending the molecule's utility beyond the oral pill.
  • Recent FDA actions are routine label management, not safety crises for EDURANT itself, the March 2026 safety-labeling update concerned the FTC/RPV/TDF combination product's hepatitis B exacerbation warning, and ongoing label updates (e.g., SPORANOX/CONCERTA) show no EDURANT-specific regulatory problems.
Bear case
  • No binary catalysts: EDURANT is already approved (2011/2024) with no pending PDUFA or pivotal readout in the next 12 months, so there is no dated event to drive a re-rating of JNJ.
  • The only scheduled JNJ-sponsored item is a tiny Phase 2 pediatric roll-over safety study (NCT02494986, 48 patients, est. primary completion 2026-08-18), a routine label-support study that will not move a $260+ stock.
  • Mature product in a competitive HIV market with ongoing generic/combo erosion risk; FDA safety-labeling updates on rilpivirine-containing combos (hepatitis B exacerbation warning, March 2026) add label burden.
● neutral
Impact
PhaseApproved (marketed); Phase 3 programs ongoing/completed (PROTEUS final analysis reported; ATLAS results pending)
Time to marketAlready on the market (FDA approved Feb 2018 for nmCRPC, expanded Sep 2019 for mCSPC). A potential perioperative label expansion from PROTEUS has no confirmed filing or approval date yet.

ERLEADA apalutamide Updated Aug 17

What to watch

Watch for (1) a J&J submission to FDA of the PROTEUS perioperative (high-risk localized prostate cancer) data, that would be the next real catalyst and would open an earlier-stage, larger patient market; and (2) the ATLAS Phase 3 readout (apalutamide + radiation), whose primary completion was estimated for mid-2026 and results are still unreported. Neither is dated, so don't trade JNJ on ERLEADA alone, at ~$3.6B of annual sales it is roughly 4% of J&J revenue, and the active-ingredient patent expiry around September 2030 caps the long-term growth story.

Bull case
  • Approved in two large prostate-cancer settings: FDA approved apalutamide for nmCRPC on Feb 14, 2018 and for mCSPC on Sep 17, 2019 (fda.gov).
  • Strong commercial momentum: ERLEADA generated $3.57B in 2025 sales, up 19.2% YoY, and $949M in Q1 2026, up 23.1% YoY.
  • PROTEUS Phase 3 final analysis (ASCO 2026, published in NEJM) showed perioperative apalutamide + ADT significantly improved metastasis-free survival and reduced the risk of metastasis or death by ~20% in high-risk localized prostate cancer, a potential new earlier-stage indication (survivornet; ccjm.org; NEJM).
Bear case
  • Intense competition in a crowded class: enzalutamide (Xtandi, Pfizer/Astellas) is the direct comparator in J&J's own head-to-head data, and darolutamide (Nubeqa, Bayer) competes in the same indications, pricing and share battles are the norm.
  • No hard catalyst on the calendar: no pending PDUFA or confirmed readout date for ERLEADA; the ATLAS Phase 3 radiation-trial primary completion was estimated at June 30, 2026 and results are still unreported (ClinicalTrials.gov; Janssen).
  • Patent cliff: the active-ingredient patent reportedly expires in September 2030, leaving roughly 44 months of exclusivity from mid-2026, after which generic erosion is a risk (ainvest).
● neutral
Impact
PhaseApproved
Time to marketApproved — marketed in the U.S. since July 31, 2009

INVEGA SUSTENNA paliperidone palmitate Updated Aug 18

What to watch

For a JNJ investor, INVEGA SUSTENNA is a mature, likely-eroding cash-flow product inside a diversified healthcare giant, not a catalyst to trade. Watch quarterly J&J earnings (pharma segment Invega franchise sales) and any FDA action on generic or biosimilar long-acting injectable paliperidone for erosion signals; a decisive bull/bear case on JNJ should be built on its oncology/immunology pipeline (e.g., RYBREVANT) and medtech, not this 2009-vintage antipsychotic.

Bull case
  • Established, long-approved franchise: FDA approval catalyst recorded 2009-07-31, with the broader Invega family (INVEGA oral 2006/2007, INVEGA HAFYERA 2015) showing J&J extended the franchise across dosing intervals.
  • Parent-company strength: JNJ closed at $262.37 (2026-08-17) with a 52-week high of $274.90, analyst consensus of 22 covering analysts at mean price target $272.50 with recommendationMean 1.91 (buy) and zero downgrades in the last 120 days.
  • Broad institutional ownership and accumulation: BlackRock ($53.9B), State Street ($34.0B) and JPMorgan ($15.1B) hold JNJ per 2026-Q2 13F data, and the 90-day evidence checklist shows multiple tracked funds adding/doubling JNJ positions in Q2 2026.
Bear case
  • No binary left: the drug-specific catalyst (approval) happened 17 years ago, the historical reaction around the 2009 approval was a -1.46% 1-day / -2.17% 5-day move, illustrating how little a single mature product moves a mega-cap.
  • Generic erosion pressure: generic oral paliperidone products (ANI Pharmaceuticals ANDA204452; Bryant Ranch ANDA218755 repackaging) carry active FDA safety-labeling actions in 2026, evidence the paliperidone market has commoditized, though these are the oral form, not the injectable.
  • Company-level sentiment is mixed: CEO Joaquin Duato sold ~102,315 shares at $261 and ~20,976 at $262 on 2026-08-13 (gross ~$26.7M + ~$5.5M per Form 4), and JNJ's FINRA daily short-volume ratio hit ~0.62 on 2026-08-17, elevated-flow flags, not a squeeze setup given short interest of only ~1.05% of estimated shares outstanding (2026-07-31).
● neutral
Impact
PhaseApproved (commercial); Phase 3 pediatric studies completed
Time to marketAlready approved and commercially marketed. A pediatric PAH label expansion is possible but its filing/decision timing is unconfirmed in available data.

OPSUMIT macitentan Updated Aug 18

What to watch

Watch for a J&J/Janssen announcement of a pediatric PAH supplemental filing for OPSUMIT, the two supporting Phase 3 pediatric studies (TOMORROW, n=165, and a 7-patient Japanese study) have completed with posted results, so a submission would be the logical next binary, but no PDUFA date is evidenced yet. For a stock trading at $262.37 with a 22-analyst mean target of $272.50 (6.7% implied upside), OPSUMIT-specific news historically moves JNJ by well under ±1-2%, so treat any headline as franchise color, not a swing factor.

Bull case
  • Pediatric growth optionality: two Phase 3 pediatric PAH studies are COMPLETED with posted results, TOMORROW (NCT02932410, 165 enrolled, completed 2025-11-27) and a Japanese study (NCT05167825, completed 2025-03-05, sponsor mapped to JNJ), setting up a potential pediatric label expansion for an already-approved drug.
  • Analyst backdrop for the owner is supportive: 31 analysts on JNJ split 22 Buy/Strong Buy vs 9 Hold and 0 Sell (period 2026-08-01), with a mean price target of $272.50 (median $280, high $305, low $190) vs a $262.37 price, ~6.7% implied upside.
  • Institutional accumulation in JNJ in 2026-Q2 13Fs (e.g., T. Rowe Price add of +39.4% of shares, Capital World Investors +29.5%, Norges Bank new position) shows large funds adding exposure to the parent company.
Bear case
  • No confirmed near-term binary: the FDA catalyst dataset shows no OPSUMIT submission or PDUFA in the last 365 days, and a pediatric sBLA timing is unconfirmed, the next hard decision could be >12 months out.
  • Small weight in a mega-cap: OPSUMIT is one product in JNJ's diversified portfolio; the local 2-year catalyst history shows JNJ FDA-approval days averaged -0.21% (1-day) and +0.05% (5-day) across 11 approvals, so even positive Opsumit headlines rarely move this stock.
  • Class/generic competition: the older ERA bosentan appears in local trial records mapped to Viatris (VTRS), a signal that generics have commoditized the ERA class, and newer PAH entrants (including injectable/add-on therapies) pressure share in a niche market.
● neutral
Impact
PhaseApproved / marketed (per public record — could not be re-verified via web this session; no approval row in local FDA tab
Time to marketAlready on the market (reported); no new approval timeline applies.

OPSYNVI macitentan and tadalafil Updated Aug 18

What to watch

For a JNJ shareholder, OPSYNVI is not a trade, it has no dated binary in the next 12 months and is a rounding error inside a ~$600B market cap, so any single-product news would barely move the stock. Watch quarterly filings for PAH revenue commentary and the competitive ralinepag/sotatercept readouts for class-level context; investors who want a PAH-specific catalyst should look at smaller single-asset developers instead.

Bull case
  • Drug classes are validated and corroborated this session: macitentan is an FDA-recognized endothelin receptor antagonist for PAH, and J&J/Janssen has completed Phase 3 macitentan PAH trials in children (NCT05167825, NCT02932410).
  • Single-pill convenience (two complementary mechanisms in one daily tablet) is a genuine patient-burden improvement vs. taking the agents separately, a low-technical-risk formulation play.
  • OPSYNVI rides J&J's huge commercial machine: JNJ is a ~$618B market-cap pharma (8-K analysis) with a buy-leaning consensus (22 analysts, mean price target $272.5, ~6.7% implied upside per local analyst snapshot).
Bear case
  • No OPSYNVI-specific record appears in any local FDA/catalyst/trial table and no scheduled binary catalyst exists for it in the next ~12 months, there is nothing to trade on.
  • Competition is real and intensifying: Merck is running Phase 3 sotatercept in PAH and United Therapeutics has a large (687-patient) Phase 3 ralinepag readout pending, and macitentan as a single agent is already genericized (Apotex, Aurobindo, Zydus ANDA safety labelings), pressuring the franchise's pricing.
  • OPSYNVI was not named among J&J's Q2 2026 growth drivers (DARZALEX, CARVYKTI, TREMFYA, SPRAVATO), underscoring that PAH is immaterial to JNJ earnings, any product-specific surprise moves the stock negligibly.
● neutral
Impact
PhaseApproved (FDA); earlier-stage label-expansion work ongoing
Time to marketAlready approved and on the U.S. market: the subcutaneous RYBREVANT FASPRO form cleared FDA as a Type 5 new-formulation approval (Dec 17 2025, BLA 761433; Feb 13 2026, BLA 761484) and in first-line NSCLC with LAZCLUZE (Jan 21 2026). The IV form, RYBREVANT, has been marketed since May 2021.

RYBREVANT FASPRO amivantamab Updated Aug 18

What to watch

There is no near-term FDA binary to trade here, the defining approvals already happened (Dec 2025–Feb 2026) and moved JNJ shares by well under 2%. Watch instead for (1) JNJ quarterly earnings commentary on RYBREVANT-franchise sales, and (2) any registration path triggered by the April 2026 head-and-neck Breakthrough Therapy Designation, plus results posting for the small Phase 2 amivantamab+docetaxel NSCLC study (completed May 2026).

Bull case
  • Already FDA-approved and commercializing, no approval risk left: RYBREVANT FASPRO cleared FDA on Dec 17 2025 (BLA 761433) and Feb 13 2026 (BLA 761484) as a Type 5 new-formulation, plus a Jan 21 2026 NSCLC approval in first-line combination with LAZCLUZE.
  • Convenience is a real differentiator: the Jan 21 2026 approval detail notes the subcutaneous form 'enables the simplest, shortest administration time for a first-line combination regimen', a meaningful clinical-practice upgrade over hour-long IV infusions of the original RYBREVANT (approved May 21 2021).
  • Expansion optionality: the U.S. FDA granted RYBREVANT FASPRO Breakthrough Therapy Designation for advanced head and neck cancer on Apr 14 2026 (per SEC-extracted catalyst on JNJ's 8-K filing), opening a second, larger indication runway beyond NSCLC.
Bear case
  • Negligible single-drug price impact: JNJ is a mega-cap (market snapshot ~$617.8B at the time of the Aug 2026 8-K report), and RYBREVANT FASPRO approvals moved the stock only roughly -0.5% to +1.5% in the 5 days after each FDA event, the catalyst is already priced in.
  • No hard, dated catalyst in the next 12 months: the head-and-neck Breakthrough Therapy Designation (Apr 14 2026) is a status with no PDUFA date or pivotal readout in the data; the two tracked Phase 2 combo studies are small (12 and 57 patients) and one completed in May 2026 with results still not posted.
  • Formulation switch, not a new mechanism: FASPRO is the same amivantamab antibody given subcutaneously rather than a novel biology, so incremental sales are largely a convenience/market-share play inside a crowded EGFR-mutant NSCLC landscape (which also faces competition in the space).
● neutral
Impact
PhaseApproved (marketed); no pivotal-stage program pending for this molecule
Time to marketAlready approved and marketed — subcutaneous Simponi approved in 2009 and the intravenous Simponi Aria form cleared FDA in July 2013 (per the recorded JNJ FDA-approval catalyst on 2013-07-18); no new approval pending for JNJ.

SIMPONI golimumab Updated Aug 17

What to watch

There is no binary JNJ event tied to Simponi, watch instead for the FDA decision on Alvotech's AVT05 golimumab biosimilar (expected ~late 2026 after its June 2026 BLA resubmission and six-month review), which would accelerate erosion of Simponi sales. For JNJ stock, Simponi is a legacy anti-TNF line item; the real drivers are the broader pharma pipeline, and the stock currently trades around $262 with a mean analyst price target of $272.50 (implied upside ~6.7%).

Bull case
  • Simponi remains an approved, marketed revenue stream for JNJ across multiple indications (RA, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis), and JNJ's SecBot-recorded FDA-approval history shows the franchise cleared regulators as recently as the July 2013 Simponi Aria approval.
  • JNJ is a fortress mega-cap: current price ~$262.37 with an analyst consensus of 15 buy + 7 strong buy vs 0 sell ratings, a mean price target of $272.50 and median of $280 (22 analysts, implied upside ~6.7%), and deep institutional ownership (BlackRock alone reported ~$53.9B of JNJ in 2026-Q2 13F data).
  • JNJ still runs combination-development work on golimumab, a completed Phase 2 trial (NCT05071664) of guselkumab + golimumab in psoriatic arthritis with results, showing the molecule retains some pipeline utility.
Bear case
  • Direct biosimilar threat is imminent: Alvotech resubmitted its AVT05 BLA, a proposed biosimilar to Simponi and Simponi Aria (golimumab), to the FDA on June 4, 2026, and the FDA's six-month review means a decision around late 2026; a U.S. golimumab biosimilar would erode Simponi pricing and share.
  • Simponi is a small, mature, ex-growth part of a vast JNJ portfolio with no upcoming JNJ-specific catalyst for this drug, no binary, just slow competitive decay; JNJ's broader forward P/E is ~23.7 with 30-day estimate revisions deteriorating (-4 net per quant data).
  • JNJ insiders have been sellers (CEO Joaquin Duato sold ~$26.7M and ~$5.5M of stock on Aug 13, 2026, plus earlier sales), and JNJ faces unrelated overhangs such as talc litigation (recorded court/enforcement rows).
● neutral
Impact
PhaseApproved
Time to marketAlready marketed — US FDA approval July 17, 2018; no launch or approval risk remaining.

SYMTUZA darunavir/cobicistat/emtricitabine/tenofovir alafenamide Updated Aug 18

What to watch

For JNJ shareholders, Symtuza is not a stock-moving catalyst, it is a mature, marketed HIV drug with no dated binary in the next year, so there is nothing to trade on the drug itself. Investors seeking HIV single-tablet-regimen exposure with actual catalysts should look to the pure-play HIV names (Gilead, ViiV) rather than JNJ; for JNJ, treat Symtuza as steady-state revenue and monitor quarterly earnings for HIV-franchise trends.

Bull case
  • First and only complete darunavir-based single-tablet regimen for HIV-1 at approval (J&J press release, PR Newswire, pharmaphorum), darunavir's high barrier to resistance differentiates it from integrase-based rivals for patients with resistance concerns.
  • Approved across the adult HIV-1 population (treatment-naive and virologically suppressed) and label expanded to pediatrics per the Nov 2023 FDA label.
  • Zero binary regulatory risk: already approved and marketed since 2018; the April 2026 FDA safety-labeling update is routine post-market monitoring, not an approval threat.
Bear case
  • The HIV single-tablet market is one of the most competitive in pharma, dominated by Gilead and ViiV regimens; Symtuza's protease-inhibitor franchise faces entrenched rivals on new prescriptions, no tool result quantified its market share, so treat share pressure as a qualitative risk.
  • April 2026 FDA safety-labeling action flags the risk of severe acute hepatitis B (HBV) exacerbations when HIV/HBV co-infected patients stop SYMTUZA, a prescribing-hurdle and liability consideration.
  • Symtuza is immaterial to JNJ's stock: no binary catalyst, no growth narrative, recent analyst target raises (TD Cowen to $300, Morgan Stanley to $294, Guggenheim to $287 in July-Aug 2026) are driven by the oncology/immunology pipeline, not HIV.
● neutral
Impact
PhaseApproved (BLA 761291); marketed
Time to marketAlready on the market — FDA-approved since Oct 2022 (BLA 761291, Type 1 new molecular entity, Priority review); latest label expansion approved Mar 2026.

TECVAYLI teclistamab Updated Aug 17

What to watch

TECVAYLI is not a JNJ stock-mover on its own: the defining binary (the March 2026 combo approval with DARZALEX FASPRO) has already passed, and JNJ does not break out TECVAYLI sales in its Q2 2026 earnings release, the myeloma franchise narrative is led by DARZALEX (+18.9% YoY) and CARVYKTI (+49.4%). For a non-medical investor, watch JNJ's quarterly oncology commentary and any future earlier-line readouts for this molecule, not TECVAYLI-specific events; the stock itself trades near consensus targets (~$272.5 mean) with very low short interest (~1.05% of est. shares outstanding).

Bull case
  • Approved and selling since Oct 25, 2022 as a first-in-class subcutaneous bispecific for relapsed/refractory multiple myeloma (Priority-review, Type 1 new molecular entity; BLA 761291), the original approval letter and label are on the public record.
  • Label is actively expanding: efficacy supplements approved Feb 2024, Nov 2024, and Mar 5, 2026, the last (Priority review) adding TECVAYLI + DARZALEX FASPRO for relapsed/refractory multiple myeloma, per the FDA catalyst record and the Mar 2026 approval letter.
  • Sits inside J&J's myeloma franchise, which is performing strongly: Q2 2026 results showed DARZALEX up 18.9% YoY and CARVYKTI up 49.4% YoY, and J&J raised full-year 2026 guidance (adjusted EPS midpoint $11.68).
Bear case
  • TECVAYLI is immaterial to a ~$600B mega-cap: JNJ's Q2 2026 earnings release did not break out TECVAYLI sales, and the stock's drivers are the broader Innovative Medicine portfolio, so no single TECVAYLI event will move the shares.
  • No hard, dated catalyst for TECVAYLI in the next ~12 months; the most recent binary (Mar 2026 combo approval) already passed, removing any near-term regulatory upside for this drug.
  • Competitive and crowded class: TECVAYLI competes in relapsed/refractory myeloma against JNJ's own cellular therapy CARVYKTI (which grew 49.4% in Q2 2026) and other companies' BCMA/CD3 bispecifics, plus the franchise anchor DARZALEX, a T-cell-engager whose label documents the class's immune-activation safety profile.
● neutral
Impact
PhaseApproved (marketed)
Time to marketAlready on the market — FDA approved oral tablets December 21, 2015, and the IV formulation July 30, 2021; pediatric (2+) labeling added later.

UPTRAVI selexipag Updated Aug 18

What to watch

Do not trade JNJ on Uptravi: it is a mature, approved product with no pending regulatory decision and it is immaterial to a ~$262 stock (mean analyst target $272.50 implies only ~7% upside, driven by JNJ's broader pipeline). Treat Uptravi as steady franchise revenue, the meaningful stock drivers are JNJ's oncology/immunology and medtech programs, not PAH.

Bull case
  • Proven efficacy: GRIPHON Phase 3 (1,156 patients) showed UPTRAVI reduced the risk of a morbidity/mortality event by 40% vs placebo (J&J Medical Connect; FDA label).
  • Broad label: approved for adults and children 2+, in oral and IV forms, with a marketing claim of ten years of safety data, the longest follow-up of any PAH therapy (uptravi.com; DailyMed).
  • Continued franchise upkeep: a supplemental FDA approval action (labeling) was recorded as recently as May 23, 2026, showing the product remains actively maintained.
Bear case
  • No catalyst: as an approved, marketed drug with only labeling-level FDA activity, Uptravi offers no near-term PDUFA/pivotal readout to trade, commercial growth is gradual, not binary.
  • Immateriality cuts both ways: Uptravi is absent from JNJ's recent FDA catalyst slate (IMAAVY, RYBREVANT, CAPLYTA, TECNIS etc. dominate), so even good news here barely registers in a stock that is up ~54% over 12 months on other drivers.
  • Competitive, niche market: PAH has multiple approved therapy classes, and Uptravi, approved in 2015, faces ongoing competition and eventual generic/loss-of-exclusivity pressure typical of an oral small molecule (approval history via FDA Drug Trials Snapshots).
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized — U.S. market since 2011 (tablets) and 2021 (oral suspension); no pending approval timeline.

XARELTO rivaroxaban Updated Aug 18

What to watch

XARELTO is a mature cash-flow product, not a share-price driver: historical 1-day stock moves around its FDA approvals were -0.61%, -0.34% and +1.17%, and J&J's 2026-08-17 close was $262.37 with a ~$600B+ market cap. Watch instead for (a) pace of generic rivaroxaban erosion, FDA safety-labeling updates for generic ANDAs from Sun Pharma, Micro Labs and NorthStar Rx confirm generics are already on the U.S. market, and (b) the revived TCPA fax class action against J&J over Xarelto's CarePath program, which the Third Circuit sent back to district court in August 2026.

Bull case
  • Established, broadly used anticoagulant franchise: original approvals date to 2011 and the oral-suspension form (NDA 215859) was approved 2021-12-20, with J&J continuing to keep labeling current (supplements approved 2025-06-17 and 2026-03-24).
  • Legal wins on the product-liability front: the Ninth Circuit affirmed dismissal of a Xarelto case against Janssen and Bayer (May 2026, assessed impact 1/10).
  • XARELTO is a tiny part of a diversified mega-cap: J&J closed at $262.37 (2026-08-17) with analyst consensus Buy (15 buy + 7 strong-buy, 9 hold, 0 sell) and mean price target $272.50, so the drug's erosion poses limited downside to the stock.
Bear case
  • Generic erosion is real and underway: FDA records show generic rivaroxaban safety-labeling updates in 2026 for Sun Pharma (ANDA208557), Micro Labs (ANDA208334) and NorthStar Rx (ANDA213114), confirming U.S. generics that undercut the brand's pricing power.
  • No binary upside left: XARELTO's defining approvals (2011, 2021) already passed, and the remaining FDA actions are routine label changes, nothing that moves a $600B+ company's shares.
  • Litigation tail-risk: the Third Circuit (Aug 2026) reversed dismissal of a TCPA class action over Xarelto CarePath faxes, reviving a claim with statutory damages of $500-$1,500 per unsolicited fax (assessed bearish, impact 4/10).
● neutral
Impact
PhasePhase 1/2 (first-in-human completed); Phase 3 ongoing
Time to marketStill in early-stage clinical development. Phase 1 results were just reported in November 2026, and Phase 3 trials are ongoing. If successful, potential approval is likely several years away (2029 or later).

pasritamig Updated Nov 9

What to watch

Pasritamig's Phase 1 results were reported on November 8, 2026, showing a 73% PSA response rate. The next catalyst is the ongoing Phase 3 trial (pasritamig + docetaxel vs docetaxel alone in mCRPC), but no specific data readout date has been announced. For JNJ, this is a very early-stage asset in a massive pipeline, so even positive Phase 3 data would have a negligible impact on JNJ's share price.

Bull case
  • Phase 1 results showed a 73% PSA response rate (11 of 15 patients at the recommended Phase 2 regimen), which is a strong early efficacy signal for a novel immunotherapy in a hard-to-treat cancer.
  • The combination of pasritamig (anti-KLK2) and JNJ-9401 (anti-PSMA) is a first-of-its-kind dual-antigen-targeted bispecific regimen designed to provide complementary T-cell activation signals.
  • Low rates of treatment-related adverse events were observed, and the regimen features every-six-week outpatient dosing designed for the community setting.
Bear case
  • Phase 1 data is from a small, uncontrolled study (15 patients at the recommended regimen) and does not establish survival benefit or superiority over existing treatments.
  • The drug is still in early clinical development; most oncology candidates fail in later-stage trials.
  • JNJ faces intense competition in mCRPC from approved therapies including docetaxel, enzalutamide, abiraterone, and other novel immunotherapies.

Other drugs in filings and trials

no drug report yet
  • TECNIS PureSee Last: Approval · Apr 14, 2026
  • ICOTYDE Last: Approval · Mar 17, 2026
  • PREZCOBIX Last: Approval · Feb 27, 2026
  • OTTAVA Robotic Surgical System Last: BLA filed · Jan 21, 2026
  • CAPLYTA Last: Approval · Dec 31, 2025
  • INLEXZO Last: Approval · Sep 9, 2025
  • LAZCLUZE Last: Approval · Aug 19, 2024
  • EDURANT PED Last: Approval · Mar 15, 2024
  • AKEEGA Last: Approval · Aug 11, 2023
  • TALVEY Last: Approval · Aug 9, 2023
  • ACUVUE THERAVISION WITH KETOTIFEN Last: Approval · Feb 25, 2022
  • BALVERSA Last: Approval · Apr 12, 2019
  • VERMOX Last: Approval · Oct 19, 2016
  • STELARA Last: Approval · Sep 23, 2016
  • INVOKAMET XR Last: Approval · Sep 20, 2016
  • YONDELIS Last: Approval · Oct 23, 2015
  • INVEGA HAFYERA Last: Approval · May 18, 2015
  • INVOKAMET Last: Approval · Aug 8, 2014
  • Erdafitinib 1 trial
  • ExPEC9V 1 trial
  • Ibrutinib 1 trial
  • Icotrokinra 1 trial
  • JNJ-63733657 1 trial
  • JNJ-64042056 1 trial
  • JNJ-89495120 1 trial
  • Milvexian 1 trial
  • Niraparib 1 trial
  • Ustekinumab 1 trial

Past FDA events & how the stock moved

40 events
DateDrugEvent1 day5 days
Oct 13, 2026RYBREVANT FASPROPriority review−3.7%−1.7%
Oct 13, 2026IMAAVYApproval−3.7%−1.7%
Apr 14, 2026TECNIS PureSeeApproval+0.3%−5.0%
Apr 14, 2026IMAAVYNDA filed+0.3%−5.0%
Apr 14, 2026RYBREVANT FASPROBreakthrough designation+0.3%−5.0%
Apr 14, 2026IMAAVYFast Track+0.3%−5.0%
Mar 17, 2026ICOTYDEApproval−2.4%−3.3%
Feb 27, 2026PREZCOBIXApproval+2.1%−1.3%
Feb 13, 2026RYBREVANT FASPROApproval−0.5%+0.5%
Jan 21, 2026OTTAVA Robotic Surgical SystemBLA filed+0.1%+4.4%
Jan 21, 2026RYBREVANT FASPROApproval+0.1%+4.4%
Dec 31, 2025OTTAVA Robotic Surgical SystemNDA filed+0.2%−0.6%
Dec 31, 2025CAPLYTAApproval+0.2%−0.6%
Dec 17, 2025RYBREVANT FASPROApproval−0.5%−0.7%
Sep 9, 2025INLEXZOApproval−1.3%−0.9%
Apr 29, 2025IMAAVYApproval+0.6%−0.6%
Jan 21, 2025RYBREVANT FASPROApproval−1.2%+2.3%
Jan 21, 2025OTTAVA Robotic Surgical SystemNDA filed−1.2%+2.3%
Aug 19, 2024LAZCLUZEApproval+0.5%+3.3%
Mar 15, 2024EDURANT PEDApproval−1.5%−2.5%
Aug 11, 2023AKEEGAApproval+0.7%+0.2%
Aug 9, 2023TALVEYApproval−0.6%−0.5%
Oct 25, 2022TECVAYLIApproval+0.7%+1.2%
Feb 25, 2022ACUVUE THERAVISION WITH KETOTIFENApproval+4.1%+7.2%
Dec 20, 2021XARELTOApproval−0.6%+1.3%
May 21, 2021RYBREVANT FASPROApproval+0.3%−0.5%
May 1, 2020DARZALEXApproval−1.2%−0.9%
Apr 12, 2019BALVERSAApproval+1.0%+1.9%
Mar 5, 2019SPRAVATOApproval+0.4%+0.5%
Jul 17, 2018SYMTUZAApproval+2.5%+3.8%
Feb 14, 2018ERLEADAApproval+1.0%−0.0%
Jul 13, 2017TREMFYAApproval+0.3%+3.3%
Oct 19, 2016VERMOXApproval−0.5%−0.7%
Sep 23, 2016STELARAApproval−1.4%−1.1%
Sep 20, 2016INVOKAMET XRApproval+1.1%+1.3%
Nov 16, 2015DARZALEXApproval+1.6%+3.6%
Oct 23, 2015YONDELISApproval+0.4%+1.5%
May 18, 2015INVEGA HAFYERAApproval+1.6%−0.7%
Jan 29, 2015PREZCOBIXApproval−1.3%+1.0%
Aug 8, 2014INVOKAMETApproval+1.2%+1.2%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
IcotrokinraA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisPhase 3Active not recruiting813Feb 10, 2027
Guselkumab SubcutaneousA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisPhase 3Active not recruiting112Feb 10, 2027
IMAAVYNipocalimab in Moderate to Severe Sjogren's DiseasePhase 3Active not recruiting655Feb 4, 2027
RYBREVANT FASPROA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerPhase 2Active not recruiting71Jan 31, 2027
IbrutinibA Long-term Extension Study of PCI-32765 (Ibrutinib)Phase 3Active not recruiting539Dec 31, 2026
CetrelimabA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderPhase 3Active not recruiting518Dec 30, 2026
JNJ-64042056A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseasePhase 2Active not recruiting55Dec 22, 2026
MilvexianA Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationPhase 3Active not recruiting20,284Dec 8, 2026
ERLEADAA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyPhase 3Active not recruiting2,517Dec 1, 2026
CARVYKTIA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaPhase 2Active not recruiting11Aug 31, 2026
EDURANTA Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric StudiesPhase 2Completed48Aug 18, 2026
DARZALEXA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaPhase 2Active not recruiting210Aug 4, 2026
ERLEADAAn Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASPhase 3Active not recruiting1,503Jun 30, 2026
JNJ-89495120A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive DisorderPhase 2Completed107Jun 25, 2026
RYBREVANT FASPROA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerPhase 2Active not recruiting57Jun 9, 2026
SPRAVATOEsketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic CholecystectomyPhase 2Completed118Jun 1, 2026
DARZALEXStudy of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaPhase 2Active not recruiting73May 31, 2026
UstekinumabAn Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation StudyPhase 3Completed41May 29, 2026
RYBREVANT FASPROA Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung CancerPhase 2Completed12May 14, 2026
TECVAYLIA Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple MyelomaPhase 2Completed40Apr 13, 2026
Macitentan TabletsEffects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPHPhase 3Terminated7Mar 26, 2026
DupilumabA Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)Phase 2Terminated256Mar 26, 2026
MetforminELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy AgingPhase 2Completed31Feb 25, 2026
JNJ-81201887A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)Phase 2Completed305Feb 23, 2026
Ad26.Mos4.HIVSafety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected AdultsPhase 2Completed28Feb 23, 2026
MilvexianA Study of Milvexian in Participants After a Recent Acute Coronary SyndromePhase 3Completed14,194Feb 6, 2026
ErdafitinibErdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerPhase 2Terminated11Feb 2, 2026
Risperidone 4mg/dayEffectiveness of Ashwagandha in Schizophrenia Patients on RisperidonePhase 2Completed80Jan 30, 2026
ERLEADAAASUR in High Risk Prostate CancerPhase 2Completed · results64Jan 22, 2026
TREMFYAA Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisPhase 3Completed48Jan 12, 2026
NiraparibNiraparib in Patients With Pancreatic CancerPhase 2Completed32Dec 31, 2025
Daratumumab and Hyaluronidase-fihjDaratumumab in STK11 Mutated NSCLCPhase 2Completed8Nov 11, 2025
JNJ-63733657A Study of JNJ-63733657 in Participants With Early Alzheimer's DiseasePhase 2Terminated · results523Oct 17, 2025
LazertinibLazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain MetastasesPhase 2Terminated14Oct 10, 2025
DARZALEXDaratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell TransplantPhase 2Terminated · results13Oct 9, 2025
IMAAVYA Study of Nipocalimab in Participants With Active Idiopathic Inflammatory MyopathiesPhase 2Completed36Sep 4, 2025
ExPEC9VA Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 YearsPhase 3Completed · results17,797Aug 27, 2025
XARELTORIvaroxaban for Stroke Patients With AntiPhospholipid SyndromePhase 2Completed43Jul 31, 2025
ERLEADAGolimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyPhase 2Terminated · results8Jul 29, 2025
PIPE-307 Dose AStudy to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple SclerosisPhase 2Completed182Jul 14, 2025